Compare GRWG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | BDTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 104.0M |
| IPO Year | 2015 | 2020 |
| Metric | GRWG | BDTX |
|---|---|---|
| Price | $1.27 | $1.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.50 | ★ $10.86 |
| AVG Volume (30 Days) | 283.3K | ★ 864.7K |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.22 | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,365,479.00 | N/A |
| Revenue This Year | $2.33 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.51 | N/A |
| 52 Week Low | $1.01 | $1.58 |
| 52 Week High | $2.40 | $4.48 |
| Indicator | GRWG | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.19 | 41.15 |
| Support Level | $1.04 | N/A |
| Resistance Level | $1.58 | $1.94 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 30.43 | 3.19 |
GrowGeneration Corp owns and operates specialty retail stores focused on hydroponic and organic gardening. The company markets and distributes nutrients, growing media, indoor and greenhouse lighting, ventilation systems, and related accessories. It operates through two reportable segments: Cultivation and Gardening, which includes its hydroponic and organic gardening business, and Storage Solutions, which includes its benching, racking, and storage solutions operations. The company generates revenue mainly from the sale of proprietary and non-proprietary products through retail stores, e-commerce platforms, wholesale distribution, and commercial sales, along with the sale and installation of commercial fixtures.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.